• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

    8/1/24 7:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email

    LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the Company's second quarter 2024 financial results will be released before market open on Thursday, August 8, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, August 8, 2024 to discuss the financial results and recent corporate highlights.

    To participate by telephone, please dial (800) 274 8461 (Domestic) or (203) 518 9848 (International). The conference ID is LENSAR. To access the live webcast, please go to the Investors section of LENSAR's website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.

    About LENSAR

    LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its ALLY® Adaptive Cataract Treatment System as a compact, highly ergonomic system utilizing an extremely fast dual-pulse laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR's advanced technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR's proprietary Streamline® software technology, which is designed to guide surgeons to achieve better outcomes.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240731564545/en/

    Get the next $LNSR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    9/6/24 9:00:13 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/29/24 6:05:46 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/23/24 6:52:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    SEC Filings

    View All

    SEC Form 10-Q filed by LENSAR Inc.

    10-Q - LENSAR, Inc. (0001320350) (Filer)

    8/7/25 4:05:33 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LENSAR, Inc. (0001320350) (Filer)

    8/7/25 7:15:25 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - LENSAR, Inc. (0001320350) (Filer)

    7/2/25 4:00:35 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Financials

    Live finance-specific insights

    View All

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports First Quarter 2025 Results and Provides Business Update

             14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

    5/8/25 7:00:42 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

    31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

    2/27/25 7:00:11 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units ("RSUs"). The RSUs were granted as of July 1, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the new empl

    7/1/25 4:01:11 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ellis Thomas B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/28/25 4:57:30 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Hammer Todd B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/28/25 4:56:24 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M was granted 7,374 shares, increasing direct ownership by 9% to 88,214 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/28/25 4:30:14 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG initiated coverage on LENSAR with a new price target

    BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

    11/22/21 6:09:40 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    3/2/21 8:10:50 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    2/24/21 6:12:20 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/14/24 4:05:39 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care